RxDoctor Payments Data

Miloni Thakker

Internal Medicine · Massapequa, NYNPI 1013412782

Payments from drug & device makers

$1,717in general payments, 2019–2025

Across 73 payments — averaging $23.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$251
  • Globus Medical$168
  • Lilly USA, LLC$146
  • Novo Nordisk$135
  • Exact Sciences$128
  • AbbVie$119
  • plus $770 from 16 others

What the payments were for

  • Food & beverage$1,717100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,717 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$115,505
Medicare patients
225
Services billed
2,734

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide48$52,736
JardianceEmpagliflozin39$52,529
OzempicSemaglutide47$44,667
Atorvastatin Calcium113$1,431
Albuterol Sulfate HfaAlbuterol Sulfate32$906
Rosuvastatin Calcium57$581
Metoprolol Succinate34$564
Pregabalin14$480
Levothyroxine Sodium33$380
Metformin Hcl44$274
Clonazepam15$247
Gabapentin22$246
Losartan Potassium29$193
Alprazolam28$179
Valsartan13$160

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$146$52,73648 claims
Boehringer IngelheimJardiance$106$52,52939 claims
Novo NordiskOzempic$135$44,66747 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Massapequa

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →